Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPIV Phase 1 in Puerto Rico
NCT03008122Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZPIV in Zika virus infection (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency and Severity of Solicited Local Events, Frequency and Severity of Solicited Systemic Events and 4 more. Started Mar 2017; status: completed.
02
Drugs
ZPIV
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03008122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008122.